Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

by Fabrice Barlesi, Steven Kao, Philippe A Cassier, Hua Fang, Frances Fan, Kathryn Allaire, Shiming Ye, Debra T Chao, William R Henner, Joel S Hayflick, Michael A McDevitt
Published 2021-02-01

Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells

by Shiming Ye, Melvin I. Fox, Nicole A. Belmar, Mien Sho, Debra T. Chao, Donghee Choi, Yuni Fang, Vivian Zhao, Stephen F. Keller, Gary C. Starling, Patricia A. Culp
Published 2017-01-01

Nuclear Factor κB is required for tumor growth inhibition mediated by enavatuzumab (PDL192), a humanized monoclonal antibody to TweakR

by James W. Purcell, Han K. Kim, Sonia G. Tanlimco, Minhtam eDoan, Melvin eFox, Peter eLambert, Debra T. Chao, Mien eSho, Keith E. Wilson, Gary C. Starling, Gary C. Starling, Patricia A. Culp
Published 2014-01-01